The molecular diagnostics company reported total revenues of $56.7 million in the quarter, and saw its testing volume grow 15 percent over Q3 2016.
Researchers at Aarhus will use Natera's liquid biopsy assay to monitor colorectal cancer patients after surgery and chemotherapy.
Several commercial NIPT providers in the US said they are planning to participate in the new program.
The company says Panorama is the only NIPT that can tell whether twins are identical or fraternal, which can impact the clinical management of a pregnancy.
Amid a flat month for the index, some firms saw large swings in their stock price. Natera led the gainers, while NantHealth led the decliners.
Natera has entered the oncology space with a ctDNA assay and sees its blood banking service as a way to eventually tap into the consumer genomics space.
Natera ran 17 percent more tests in Q2 than it did in the prior-year period, generating $53.6 million in total revenues.
Upgrades from two investment banks appeared to boost Quidel's shares, while a medical policy update from Aetna may have dampened Natera's.
In a revised medical policy, Aetna said it would continue to cover NIPT for high-risk pregnancies, but not average-risk ones.
Counsyl believes its data is robust, while Natera has called the methodology and conclusions "gratuitously wrong." Both published opposing response letters this week.